Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Int J Cancer
    September 2021
  1. HUGEN N, Kanne H, Simmer F, van de Water C, et al
    Umbilical metastases: Real-world data shows abysmal outcome.
    Int J Cancer. 2021;149:1266-1273.
    >> Share

  2. IYOSHI S, Yoshihara M, Nakamura K, Sugiyama M, et al
    Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer.
    Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33770.
    >> Share

    August 2021
  3. WANG T, Jake-Schoffman DE, Townsend MK, Vinci C, et al
    Early life physical activity and risk of ovarian cancer in adulthood.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33760.
    >> Share

    July 2021
  4. COUGHLAN AY, Testa G
    Exploiting epigenetic dependencies in ovarian cancer therapy.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33727.
    >> Share

    June 2021
  5. DARELIUS A, Kristjansdottir B, Dahm-Kahler P, Strandell A, et al
    Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714.
    >> Share

    May 2021
  6. WANG T, Townsend MK, Eliassen AH, Terry KL, et al
    Pre- and post-diagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33676.
    >> Share

    April 2021
  7. DIMOU NL, Papadimitriou N, Mariosa D, Johansson M, et al
    Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
    Int J Cancer. 2021;148:1625-1636.
    >> Share

  8. CHRISTAKOUDI S, Pagoni P, Ferrari P, Cross AJ, et al
    Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer. 2021;148:1637-1651.
    >> Share

    March 2021
  9. CROSBIE EJ, Flaum N, Harkness EF, Clayton RD, et al
    Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Int J Cancer. 2021;148:1155-1163.
    >> Share

    February 2021
  10. YANG J, Sasamoto N, Babic A, Vitonis AF, et al
    Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses' Health Studies.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33531.
    >> Share

    January 2021
  11. BETHEA TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, et al
    First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493.
    >> Share

  12. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    >> Share

    November 2020
  13. AN Y, Yang Q
    Tumor-associated macrophage targeted therapeutics in ovarian cancer.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33408.
    >> Share

  14. KESSOUS R, Wissing MD, Laskov I, Abitbol J, et al
    Multiple lines of chemotherapy for patients with high-grade ovarian cancer - predictors for response and effect on survival.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33395.
    >> Share

    October 2020
  15. MAJIDI A, Na R, Jordan SJ, De Fazio A, et al
    Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33333.
    >> Share

    September 2020
  16. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    >> Share

  17. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    >> Share

  18. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    >> Share

    August 2020
  19. TODISCO E, Gigli F, Mantiero M, Sammassimo S, et al
    Clinical presentation, diagnosis and management of Therapy-Related Hematological Disorders in Women with Epithelial Ovarian Cancer treated with Chemotherapy and Poly-ADP-Ribose Polymerase Inhibitors (PARP-i): a single Center experience.
    Int J Cancer. 2020 Aug 28. doi: 10.1002/ijc.33269.
    >> Share

    July 2020
  20. PANOUTSOPOULOU K, Avgeris M, Magkou P, Mavridis K, et al
    miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33182.
    >> Share

    June 2020
  21. HANSEN JM, Nagle CM, Ibiebele TI, Grant PT, et al
    A healthy lifestyle and survival among women with ovarian cancer.
    Int J Cancer. 2020 Jun 16. doi: 10.1002/ijc.33155.
    >> Share

    April 2020
  22. JIANG YT, Gong TT, Zhang JY, Li XQ, et al
    Infertility and ovarian cancer risk: evidence from nine prospective cohort studies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33012.
    >> Share

  23. JUNG M, Gao J, Cheung L, Bongers A, et al
    ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Int J Cancer. 2020 Apr 10. doi: 10.1002/ijc.33005.
    >> Share

  24. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    >> Share

    March 2020
  25. GONG Y, Yang J, Wang Y, Xue L, et al
    Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites.
    Int J Cancer. 2020 Mar 24. doi: 10.1002/ijc.32990.
    >> Share

  26. SINGH A, Gupta S, Badarukhiya JA, Sachan M, et al
    "Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer".
    Int J Cancer. 2020 Mar 19. doi: 10.1002/ijc.32984.
    >> Share

  27. ESSERS PBM, van der Heijden M, Vossen D, de Roest RH, et al
    Ovarian cancer derived copy number alterations signatures are prognostic in chemoradiotherapy treated head and neck squamous cell carcinoma.
    Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32962.
    >> Share

    February 2020
  28. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    >> Share

  29. BENVENUTO G, Todeschini P, Paracchini L, Calura E, et al
    Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    Int J Cancer. 2020 Feb 25. doi: 10.1002/ijc.32935.
    >> Share

  30. KOTSOPOULOS J, Narod SA
    Prophylactic salpingectomy for the prevention of ovarian cancer; who should we target?
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32916.
    >> Share

  31. REIJNEN C, Kusters-Vandevelde HVN, Ligtenberg MJL, Bulten J, et al
    Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907.
    >> Share

    January 2020
  32. HANNIBAL CG, Frederiksen K, Vang R, Kurman RJ, et al
    Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide-based study.
    Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864.
    >> Share

  33. YOSHIHARA M, Kajiyama H, Yokoi A, Sugiyama M, et al
    Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32854.
    >> Share

    December 2019
  34. RAMRAJ SK, Elayapillai SP, Pelikan RC, Zhao YD, et al
    Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32830.
    >> Share

  35. WOLF D, Fiegl H, Zeimet AG, Wieser V, et al
    High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
    Int J Cancer. 2019 Dec 4. doi: 10.1002/ijc.32818.
    >> Share

    November 2019
  36. WANG T, Townsend MK, Simmons V, Terry KL, et al
    Pre- and Post- Diagnosis Smoking and Survival Following Diagnosis with Ovarian Cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32773.
    >> Share

  37. SOKOLENKO AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, et al
    Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776.
    >> Share

    October 2019
  38. KRATZER TB, Weinstein SJ, Albanes D, Mondul AM, et al
    Vitamin D Binding Protein and Risk of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Int J Cancer. 2019 Oct 29. doi: 10.1002/ijc.32758.
    >> Share

  39. FELIX AS, McLaughlin EM, Caan BJ, Cohn DE, et al
    Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32740.
    >> Share

  40. LEE YJ, Kim D, Shim JE, Bae SJ, et al
    Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32729.
    >> Share

  41. SIMIN J, Rulla MT, Callens S, Engstrand L, et al
    Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32706.
    >> Share

  42. QIU JJ, Lin XJ, Tang XY, Zheng TT, et al
    Long Noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32692.
    >> Share

    September 2019
  43. LINK T, Passek S, Wimberger P, Frank K, et al
    Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32676.
    >> Share

  44. LYU T, Jiang Y, Jia N, Che X, et al
    SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32673.
    >> Share

  45. YI T, Feng Y, Sundaram R, Tie Y, et al
    Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Int J Cancer. 2019;145:1209-1220.
    >> Share

    August 2019
  46. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
    Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
    >> Share

  47. RICE MS, Poole EM, Willett WC, Tworoger SS, et al
    Adult Dietary Fat Intake and Ovarian Cancer Risk.
    Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32635.
    >> Share

  48. RAY-COQUARD I, Cibula D, Mirza MR, Reuss A, et al
    Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
    Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32606.
    >> Share

    July 2019
  49. RAAB M, Kobayashi NF, Becker S, Kurunci-Csacsko E, et al
    Boosting the apoptotic response of high grade serous ovarian cancers with CCNE1-amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32559.
    >> Share

  50. ZHU Q, Zhang J, Chen Y, Hu Q, et al
    Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.
    >> Share

    June 2019
  51. GRUNDY A, Ho V, Abrahamowicz M, Parent ME, et al
    Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: a case-control study.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32513.
    >> Share

    May 2019
  52. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
    Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
    >> Share

    April 2019
  53. CABASAG CJ, Arnold M, Butler J, Inoue M, et al
    The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32322.
    >> Share

    March 2019
  54. NURMI A, Muranen TA, Pelttari LM, Kiiski JI, et al
    Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Int J Cancer. 2019 Mar 30. doi: 10.1002/ijc.32309.
    >> Share

  55. LI H, Zhang W, Niu C, Lin C, et al
    Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32293.
    >> Share

  56. BALLABIO S, Craparotta I, Paracchini L, Mannarino L, et al
    Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number variation in 3p26.2 and 8q24.3.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32288.
    >> Share

    February 2019

  57. Expression of Concern: "Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells" by Hua Yang, Lili He, Patricia Kruk, Santo V. Nicosia and Jin Q. Cheng.
    Int J Cancer. 2019 Feb 27. doi: 10.1002/ijc.32225.
    >> Share

  58. HE Y, Gu Z, Zhu Q, Chen M, et al
    CA125 over-release behavior following a 75-gram oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32237.
    >> Share

    January 2019
  59. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
    Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
    >> Share

  60. TRABERT B, Michels KA, Anderson GL, Brinton LA, et al
    Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32157.
    >> Share

  61. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
    Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
    >> Share

    December 2018
  62. FORTNER RT, Poole EM, Wentzensen NA, Trabert B, et al
    Ovarian cancer risk factors by tumor aggressiveness: an analysis from the Ovarian Cancer Cohort Consortium.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32075.
    >> Share

    November 2018
  63. KIM S, Wang M, Tyrer JP, Jensen A, et al
    A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
    >> Share

  64. SCHUBERT S, van Luttikhuizen JL, Auber B, Schmidt G, et al
    The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31992.
    >> Share

    September 2018
  65. LIU Z, Zhang S, Hou F, Zhang C, et al
    Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31887.
    >> Share

  66. MONDAL S, Roy D, Sarkar Bhattacharya S, Jin L, et al
    Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
    Int J Cancer. 2018 Sep 18. doi: 10.1002/ijc.31868.
    >> Share

  67. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    >> Share

    August 2018
  68. ZHANG C, Wang X, Anaya Y, Parodi L, et al
    Distinct Molecular Pathways in Ovarian Endometrioid Adenocarcinoma with Concurrent Endometriosis.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31768.
    >> Share

  69. JIN C, Liu Z, Li Y, Bu H, et al
    PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31800.
    >> Share

  70. LU X, Li Y, Xia B, Bai Y, et al
    Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based non-targeted and targeted analyses.
    Int J Cancer. 2018 Aug 16. doi: 10.1002/ijc.31807.
    >> Share

    July 2018
  71. AKINWUNMI B, Vitonis AF, Titus L, Terry KL, et al
    Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31758.
    >> Share

  72. CHEN HJ, Huang RL, Liew PL, Su PH, et al
    GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31750.
    >> Share

  73. AUSTRIA T, Marion C, Yu V, Widschwendter M, et al
    Mechanism of cytokinesis failure in ovarian cystadenomas with defective brca1 and p53 pathways.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31659.
    >> Share

    June 2018
  74. KO KP, Kim SJ, Huzarski T, Gronwald J, et al
    The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
    Int J Cancer. 2018;142:2263-2272.
    >> Share

    May 2018
  75. BIZZARO F, Falcetta F, D'Agostini E, Decio A, et al
    Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31596.
    >> Share

  76. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.
    Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581.
    >> Share

  77. HUANG RL, Chen HJ, Chen LY, Chao TK, et al
    Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
    Int J Cancer. 2018 May 7. doi: 10.1002/ijc.31580.
    >> Share

    April 2018
  78. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31535.
    >> Share

  79. AGOSTINI A, Brunetti M, Davidson B, Trope CG, et al
    Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31418.
    >> Share

    March 2018
  80. PAPAEVANGELOU E, Almeida GS, Box C, deSouza NM, et al
    The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31392.
    >> Share

    February 2018
  81. KAAKS R, Fortner RT, Husing A, Barrdahl M, et al
    Tumor-associated auto-antibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31335.
    >> Share

  82. LIEW PL, Huang RL, Weng YC, Fang CL, et al
    Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31324.
    >> Share

    January 2018
  83. LOKKEGAARD ECL, Morch LS
    Tibolone and risk of gynecological hormone sensitive cancer.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31267.
    >> Share

    December 2017
  84. KHAIRALLAH AS, Genestie C, Auguste A, Leary A, et al
    Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31200.
    >> Share

  85. REIMER D, Boesch M, Wolf D, Marth C, et al
    Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31186.
    >> Share

    November 2017
  86. FORTNER RT, Schock H, Le Cornet C, Husing A, et al
    Ovarian Cancer Early Detection by Circulating CA125 in the context of Anti-CA125 Autoantibody Levels: Results from the EPIC cohort.
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31164.
    >> Share

  87. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    >> Share

  88. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    >> Share

    October 2017
  89. FELIX AS, Brasky TM, Cohn DE, Mutch DG, et al
    Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
    Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31127.
    >> Share

  90. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
    Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
    >> Share

    September 2017
  91. GAITSKELL K, Green J, Pirie K, Barnes I, et al
    Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31063.
    >> Share

  92. RICE MS, Rist PM, Winter AC, Kurth T, et al
    Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31062.
    >> Share

  93. JUNG S, Allen N, Arslan AA, Baglietto L, et al
    Anti-Mullerian Hormone and risk of ovarian cancer in nine cohorts.
    Int J Cancer. 2017 Sep 18. doi: 10.1002/ijc.31058.
    >> Share

    August 2017
  94. BABIC A, Harris HR, Vitonis AF, Titus LJ, et al
    Menstrual pain and risk of epithelial ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Int J Cancer. 2017 Aug 22. doi: 10.1002/ijc.31010.
    >> Share

  95. WU YH, Huang YF, Chang TH, Chou CY, et al
    Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-kappaB-mediated IKKbeta expression.
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.30932.
    >> Share

  96. MORCH LS, Dehlendorff C, Baandrup L, Friis S, et al
    Use of antidepressants and risk of epithelial ovarian cancer.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30919.
    >> Share

    July 2017
  97. WU AH, Pearce CL, Lee A, Tseng C, et al
    Timing of births and oral contraceptive use influences ovarian cancer risk.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30910.
    >> Share

  98. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    >> Share

  99. KRITSCH D, Hoffmann F, Steinbach D, Jansen L, et al
    Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30860.
    >> Share

    June 2017
  100. BIXEL K, Saini U, Bid HK, Fowler J, et al
    Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Int J Cancer. 2017 Jun 24. doi: 10.1002/ijc.30847.
    >> Share

  101. JAREID M, Licaj I, Olsen KS, Lund E, et al
    Does an epidemiological comparison support a common cellular lineage for similar subtypes of postmenopausal uterine and ovarian carcinoma? The Norwegian Women and Cancer Study.
    Int J Cancer. 2017 Jun 8. doi: 10.1002/ijc.30826.
    >> Share

    April 2017
  102. VERDOODT F, Kjaer Hansen M, Kjaer SK, Pottegard A, et al
    Statin use and mortality among ovarian cancer patients: A population-based cohort study.
    Int J Cancer. 2017 Apr 15. doi: 10.1002/ijc.30738.
    >> Share

    March 2017
  103. STALBERG K, Kjolhede P, Bjurberg M, Borgfeldt C, et al
    Risk factors for lymph node metastases in women with endometrial cancer: A population-based, nation-wide register study - On behalf of the Swedish gynecological cancer group (SweGCG).
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30707.
    >> Share

  104. COBURN SB, Bray F, Sherman ME, Trabert B, et al
    International patterns and trends in ovarian cancer incidence, overall and by histologic subtype.
    Int J Cancer. 2017 Mar 3. doi: 10.1002/ijc.30676.
    >> Share

    February 2017
  105. SHI T, Wang P, Xie C, Yin S, et al
    BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Int J Cancer. 2017 Feb 8. doi: 10.1002/ijc.30633.
    >> Share

    January 2017
  106. PRAESTEGAARD C, Jensen A, Jensen SM, Nielsen TS, et al
    Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 19 studies.
    Int J Cancer. 2017 Jan 7. doi: 10.1002/ijc.30600.
    >> Share

    December 2016
  107. TANG FH, Hsieh TH, Hsu CY, Lin HY, et al
    KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.
    Int J Cancer. 2016 Dec 29. doi: 10.1002/ijc.30591.
    >> Share

  108. GARCIA-SANZ P, Trivino JC, Mota A, Perez Lopez M, et al
    Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
    Int J Cancer. 2016 Dec 20. doi: 10.1002/ijc.30573.
    >> Share

  109. JONES NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, et al
    Distinct molecular landscapes between endometrioid and non-endometrioid uterine carcinomas.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30537.
    >> Share

    October 2016
  110. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    >> Share

  111. PERES LC, Bandera EV, Qin B, Guertin KA, et al
    Dietary Inflammatory Index and Risk of Epithelial Ovarian Cancer in African American Women.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30467.
    >> Share

    September 2016
  112. HARRIS HR, Titus LJ, Cramer DW, Terry KL, et al
    Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.
    Int J Cancer. 2016 Sep 26. doi: 10.1002/ijc.30441.
    >> Share

  113. KRAUS C, Hoyer J, Vasileiou G, Wunderle M, et al
    Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30428.
    >> Share

    August 2016
  114. MARSHALL AD, van Geldermalsen M, Otte NJ, Anderson L, et al
    LAT1 is a Putative Therapeutic Target in Endometrioid Endometrial Carcinoma.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30371.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016